Well reported studies of labelling issues give unfair bad press to CBD – but it is an issue the industry urgently needs to address, according to speakers at the Food and Drug Law Institute’s annual conference
Submit your access request to explore how it can streamlines access to critical cannabis insights
"*" indicates required fields